Talk by Dr. Claire Foldi, Monash University Melbourne, Australia
Targeting cognitive inflexibility to treat anorexia nervosa – insights into the effects of psilocybin in animal models
- Date: Jul 6, 2022
- Time: 02:00 PM c.t. - 03:00 PM (Local Time Germany)
- Speaker: Dr. Claire Foldi
- Dr Claire Foldi is a Senior Research Fellow and Group Leader at the Monash Biomedicine Discovery Institute where she leads a program of research focused on the neurobiological underpinnings of anorexia nervosa. Much of this work has centred on how cognition, behaviour and activity within specific neural circuits are involved in the development of pathological weight loss in the activity-based anorexia (ABA) rat model. The Foldi Group is now investigating how psilocybin acts in the brain to modify cognitive behaviour in order to gain insight into its therapeutic potential for anorexia nervosa with funding from the National Health and Medical Research Council of Australia. Dr Foldi also co-leads the Workforce Development stream of the newly-established National Centre for Eating Disorders Research and Translation, and contributes to research projects within the Monash Centre for Consciousness and Contemplative Studies (M3CS) and the Monash Neuromedicines Discovery Centre (NDC).
- Location: MPI for Metabolism Research, Gleueler Strasse 50, 50931 Köln
- Room: Seminar room 1
- Host: Dr. Weiyi Chen
- Contact: firstname.lastname@example.org
Psychedelics, including psilocybin and LSD, are undergoing a “renaissance” as possible treatments for a range of psychiatric and neurological disorders, especially because of their fast onset of therapeutic activity. There has been a rapid push to clinical trials since the 2018 designation of psilocybin as a “breakthrough therapy” by the US FDA, based on its efficacy in treatment-resistant depression, including 4 clinical trials currently underway in patients with anorexia nervosa (AN). While the outcomes of these trials will show efficacy one way or the other, it is imperative to understand the biological mechanisms through which psilocybin may act to produce therapeutic outcomes, in order to best direct treatment to individuals likely to respond. This is especially important given the climate of intense media hype that may bias the outcomes of clinical trials based on an expectation of efficacy. We have tested the effects of a single dose of psilocybin on the development of pathological weight loss in the most well-established animal model of AN, known as activity-based anorexia, and suggest a role for reinforcement learning and behavioural flexibility in the positive effects of psilocybin on energy balance. We are now focused on uncovering the neurobiological substrates that underpin these effects, by examining changes in serotonin receptor expression and the brain-derived neurotropic factor (BDNF) signalling pathway.